Literature DB >> 19275240

Nontargeted urinary metabolite profiling of a mouse model of Crohn's disease.

Hui-Ming Lin1, Shelley I Edmunds, Nuala A Helsby, Lynnette R Ferguson, Daryl D Rowan.   

Abstract

Crohn's disease is an inflammatory disorder of the bowel, believed to arise from the dysregulation of intestinal mucosal immunity. The interleukin-10-deficient (IL10-/-) mouse, which develops intestinal inflammation in the presence of gut microflora, serves as a mouse model of Crohn's disease. Nontargeted urinary metabolite profiling was carried out to identify systemic metabolic changes associated with the development of intestinal inflammation caused by IL10-deficiency. Spot urine samples, collected from IL10-/- and wildtype mice at ages 5.5, 7, 8.5, and 10.5 weeks old were analyzed by gas chromatography-mass spectrometry (GCMS). The data were analyzed using XCMS software, multiple t tests, and ANOVA. Among the key metabolic differences detected were elevated urinary levels of xanthurenic acid and fucose in IL10-/- mice relative to wildtype, indicating upregulation of tryptophan catabolism and perturbed fucosylation in IL10-/- mice. Three short-chain dicarboxylic acid metabolites were decreased in urine of IL10-/- mice relative to wildtype, suggesting the downregulation of fatty acid oxidation in IL10-/- mice. These metabolic differences were reproducible in an independent set of mice. This study demonstrates that nontargeted GCMS metabolite profiling of IL10-/- mice can provide insights into the metabolic effects of IL10-deficiency and identify potential markers of intestinal inflammation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19275240     DOI: 10.1021/pr800999t

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  18 in total

Review 1.  Diagnosis of gastroenterological diseases by metabolome analysis using gas chromatography-mass spectrometry.

Authors:  Masaru Yoshida; Naoya Hatano; Shin Nishiumi; Yasuhiro Irino; Yoshihiro Izumi; Tadaomi Takenawa; Takeshi Azuma
Journal:  J Gastroenterol       Date:  2011-11-02       Impact factor: 7.527

2.  Identification of urinary biomarkers of colon inflammation in IL10-/- mice using Short-Column LCMS metabolomics.

Authors:  Don Otter; Mingshu Cao; Hui-Ming Lin; Karl Fraser; Shelley Edmunds; Geoff Lane; Daryl Rowan
Journal:  J Biomed Biotechnol       Date:  2010-12-06

Review 3.  Biomarkers in inflammatory bowel disease: current practices and recent advances.

Authors:  Heba N Iskandar; Matthew A Ciorba
Journal:  Transl Res       Date:  2012-02-01       Impact factor: 7.012

4.  Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases.

Authors:  Tomasz Dawiskiba; Stanisław Deja; Agata Mulak; Adam Ząbek; Ewa Jawień; Dorota Pawełka; Mirosław Banasik; Agnieszka Mastalerz-Migas; Waldemar Balcerzak; Krzysztof Kaliszewski; Jan Skóra; Piotr Barć; Krzysztof Korta; Kornel Pormańczuk; Przemyslaw Szyber; Adam Litarski; Piotr Młynarz
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

5.  Host-microbiome interactions: the aryl hydrocarbon receptor as a critical node in tryptophan metabolites to brain signaling.

Authors:  Ning Ma; Ting He; Lee J Johnston; Xi Ma
Journal:  Gut Microbes       Date:  2020-05-13

Review 6.  Indoleamine 2,3 dioxygenase in intestinal disease.

Authors:  Matthew A Ciorba
Journal:  Curr Opin Gastroenterol       Date:  2013-03       Impact factor: 3.287

Review 7.  Metabolomics--a novel window into inflammatory disease.

Authors:  Martin Fitzpatrick; Stephen P Young
Journal:  Swiss Med Wkly       Date:  2013-01-21       Impact factor: 2.193

8.  Blood volatile compounds as biomarkers for colorectal cancer.

Authors:  Changsong Wang; Peng Li; Ailing Lian; Bo Sun; Xiaoyang Wang; Lei Guo; Chunjie Chi; Shanshan Liu; Wei Zhao; Suqi Luo; Zhigang Guo; Yang Zhang; Chaofu Ke; Guozhu Ye; Guowang Xu; Fengmin Zhang; Enyou Li
Journal:  Cancer Biol Ther       Date:  2013-11-01       Impact factor: 4.742

Review 9.  Metabolomics: is it useful for inflammatory bowel diseases?

Authors:  Martin Storr; Hans J Vogel; Rudolf Schicho
Journal:  Curr Opin Gastroenterol       Date:  2013-07       Impact factor: 3.287

10.  Quantitative metabolomic profiling of serum, plasma, and urine by (1)H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals.

Authors:  Rudolf Schicho; Rustem Shaykhutdinov; Jennifer Ngo; Alsu Nazyrova; Christopher Schneider; Remo Panaccione; Gilaad G Kaplan; Hans J Vogel; Martin Storr
Journal:  J Proteome Res       Date:  2012-05-17       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.